Medical Specialty >> Pharmacy
Fentanyl Now the No. 1 Opioid OD Killer
9:00 AM CST.
By Steven ReinbergHealthDay Reporter Read article
- FDA Warns of Raw Cookie Dough Dangers
- AHA: New Report Emphasizes Safety of Statins
- Catnip: The ‘Why’ Behind Cats’ Favorite High
- Opioids Exact Another Toll on Newborns: Smaller Heads
JOURNAL UPDATE
Reference Infliximab, Biosimilar Equivalent for Crohn’s Disease
12:00 PM CST. CT-P13 is equivalent to reference product in primary outcome; no difference in safety outcomes- Consensus Decision Pathway Developed for Tobacco Cessation
- Patients May Become Immune to Botulinum Toxin Treatments
- AHA Scientific Statement: Low Risk of Side Effects for Statins
MONTHLY JOURNAL SUMMARY
November 2018 Briefing - Pharmacy
December 03, 2018. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
Ted Lain, MD.
Clinical trial investigator Dr. Ted Lain comments on the results of the OPAL study, a Phase 2b clinical trial which evaluated the efficacy of a novel topical gel formulation of the antibiotic minocycline (BPX-01) in reducing the number of inflammatory lesions in patients with moderate-to-severe inflammatory,…
Bevacizumab for breast cancer: FDA grants a stay of execution
Dr. Alberto De la Guerra.
The Food and Drug Administration has after repeated delays proposed removing metastatic breast cancer as an indication from the Avastin label. The proposal is being contested by Roche/Genentech, the drug’s maker. In this article we review the evidence for and against this decision.
MEDICAL FOCUS
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By MrRobinGreat articles. learnt a lot from it.
